| Segment Reporting [Table Text Block] |
| | | As of June 30, 2026 | | | As of December 31, 2025 | |
| | | Biopharma | | | CDMO | | | Consolidated | | | Biopharma | | | CDMO | | | Consolidated | |
| Cash and cash equivalents | | $ | 1,991 | | | $ | 117 | | | $ | 2,108 | | | $ | 12,277 | | | $ | 368 | | | $ | 12,645 | |
| Inventory, net | | | 750 | | | $ | — | | | $ | 750 | | | | — | | | $ | — | | | $ | — | |
| Prepaid expenses and other current assets | | | 78 | | | | 446 | | | | 524 | | | | 156 | | | | 190 | | | | 346 | |
| Property and equipment, net | | | 26 | | | | 12,317 | | | | 12,343 | | | | 34 | | | | 12,607 | | | | 12,641 | |
| Deferred offering costs | | | 631 | | | | — | | | | 631 | | | | 136 | | | | — | | | | 136 | |
| Licensed technology, net | | | 2,243 | | | | — | | | | 2,243 | | | | 2,243 | | | | — | | | | 2,243 | |
| Operating lease right-of-use assets, net | | | — | | | | 9,835 | | | | 9,835 | | | | — | | | | — | | | | — | |
| Goodwill | | | — | | | | 3,457 | | | | 3,457 | | | | — | | | | 3,457 | | | | 3,457 | |
| Restricted cash | | | 368 | | | | — | | | | 368 | | | | — | | | | — | | | | — | |
| Other assets | | | 130 | | | | 84 | | | | 214 | | | | 124 | | | | — | | | | 124 | |
| Total consolidated assets of continuing operations | | $ | 6,217 | | | $ | 26,256 | | | $ | 32,473 | | | $ | 14,970 | | | $ | 16,622 | | | $ | 31,592 | |
| | | Three Months Ended June30, 2026 | | | Three Months Ended June 30, 2025 | |
| | | Biopharma | | | CDMO | | | Consolidated | | | Biopharma | | | CDMO | | | Consolidated | |
| Operating Expenses | | | | | | | | | | | | | | | | | | | | | | | | |
| Research and development | | $ | 1,544 | | | $ | 1,160 | | | $ | 2,704 | | | $ | 655 | | | $ | — | | | $ | 655 | |
| Selling, general and administrative | | | 1,431 | | | | 2,289 | | | | 3,720 | | | | 1,023 | | | | — | | | | 1,023 | |
| Total operating expenses | | | 2,975 | | | | 3,449 | | | | 6,424 | | | | 1,678 | | | | — | | | | 1,678 | |
| Other expense (income) | | | | | | | | | | | | | | | | | | | | | | | | |
| Change in fair value of derivative liability | | | 47 | | | | — | | | | 47 | | | | — | | | | — | | | | — | |
| Interest income | | | 11 | | | | — | | | | 11 | | | | 3 | | | | — | | | | 3 | |
| Interest expense | | | (691 | ) | | | — | | | | (691 | ) | | | — | | | | — | | | | — | |
| Net other (expense) income | | | (633 | ) | | | — | | | | (633 | ) | | | 3 | | | | — | | | | 3 | |
| Net loss from operations before discontinued operations | | $ | (3,608 | ) | | $ | (3,449 | ) | | $ | (7,057 | ) | | $ | (1,675 | ) | | $ | — | | | $ | (1,675 | ) |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Six Months Ended June 30, 2026 | | | Six Months Ended June 30, 2025 | |
| | | Biopharma | | | CDMO | | | Consolidated | | | Biopharma | | | CDMO | | | Consolidated | |
| Operating Expenses | | | | | | | | | | | | | | | | | | | | | | | | |
| Research and development | | $ | 2,401 | | | $ | 2,157 | | | $ | 4,558 | | | $ | 990 | | | $ | — | | | $ | 990 | |
| Selling, general and administrative | | | 3,485 | | | | 4,015 | | | | 7,500 | | | | 2,065 | | | | — | | | | 2,065 | |
| Total operating expenses | | | 5,886 | | | | 6,172 | | | | 12,058 | | | | 3,055 | | | | — | | | | 3,055 | |
| Other expense (income) | | | | | | | | | | | | | | | | | | | | | | | | |
| Change in fair value of derivative liability | | | 80 | | | | — | | | | 80 | | | | — | | | | — | | | | — | |
| Interest income | | | 35 | | | | — | | | | 35 | | | | 7 | | | | — | | | | 7 | |
| Interest expense | | | (1,339 | ) | | | — | | | | (1,339 | ) | | | — | | | | — | | | | — | |
| Net other (expense) income | | | (1,224 | ) | | | — | | | | (1,224 | ) | | | 7 | | | | — | | | | 7 | |
| Net loss from operations before discontinued operations | | $ | (7,110 | ) | | $ | (6,172 | ) | | $ | (13,282 | ) | | $ | (3,048 | ) | | $ | — | | | $ | (3,048 | ) |
|